Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

    Sep 27, 2023, 09:06 AM by
    LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
    Full story
  • Cytel continues expansion of market access and medical communication capabilities with the acquisition of co.faktor

    Sep 27, 2023, 09:06 AM by
    Cytel Inc. has acquired the Berlin-based company co.faktor GmbH.
    Full story
  • Discovery Park selects 13 start-ups to join Discovery Spark life science programme

    Sep 27, 2023, 09:06 AM by
    Thirteen life science start-ups have been accepted onto Discovery Park’s new business support programme and competition, Discovery Spark. The eight-week Discovery Spark programme will equip the early-stage companies with the necessary skills to catalyse their business growth plans and gives them the chance to win a business support package worth over £100,000.
    Full story
  • Follow the Money: NIH Establishes “Multi-Omics” Data Research Center, Huge Funding for Advancing AI Platform

    Sep 27, 2023, 01:00 AM by User Not Found
    Bio-IT World| Moderna and Immatics launch a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need; The National Institutes of Health is establishing the Multi-Omics for Health and Disease Consortium to advance the generation and analysis of “multi-omic” data for human health research; Generate:Biomedicines has secured huge funding to advance its AI platform used to increase precision, speed, and probability of success of novel therapeutics; more.
    Full story
  • Sygnature Discovery successfully identifies potent SHP2 degrader compounds using its proprietary targeted protein degrader platform, CHARMED, in collaboration with Japanese specialty chemical company, UBE Corporation

    Sep 26, 2023, 09:29 AM by
    Full story
  • The Why, How, and Hope of Generative AI and Data Technology With Bryn Roberts

    Sep 26, 2023, 01:00 AM by User Not Found
    Bio-IT World| As artificial intelligence continues to rapidly develop, it is tempting for organizations to rush into using AI—or at least an AI buzzword. In the latest episode of the Trends from the Trenches podcast, host Stan Gloss channels Simon Sinek and challenges Bryn Roberts to start with why.
    Full story
  • Optibrium Releases Powerful Metabolism Prediction Capability in Next Generation StarDrop Software

    Sep 25, 2023, 18:53 PM by
    Optibrium, a leading developer of software and AI solutions for drug discovery, today launched the latest version of its drug discovery platform, StarDrop 7.5, introducing a powerful module for drug metabolism prediction.
    Full story
  • DRIVING PRECISION MEDICINE FORWARD: BIO-IT WORLD EUROPE CONVENES IN LONDON 29-30 NOVEMBER 2023

    Sep 25, 2023, 18:53 PM by
    Bio-IT World Europe will convene in London 29-30 November 2023 to foster collaboration among the UK and Europe's biopharma and technology leaders who are forging new frontiers in precision medicine.
    Full story
  • CD Genomics Unveils Cutting-Edge DNA 6mA Sequencing Service for Epigenomic Research

    Sep 25, 2023, 08:55 AM by
    Full story
  • CD Genomics Unveils Genotyping by Sequencing (GBS) -Revolutionizing Genomic Research

    Sep 25, 2023, 08:55 AM by
    Full story
  • Creative Enzymes Unveils Custom Blends Product Line for Bioprocessing Solutions

    Sep 25, 2023, 08:55 AM by
    Full story
  • CD Genomics Redefines RNA Sequencing with Revolutionary Ultra Low RNA Sequencing Technology

    Sep 25, 2023, 08:55 AM by
    Full story
  • Creative Enzymes Launches Diamine Oxidase (Food-Grade) for Enhanced Food Safety and Digestive Health

    Sep 25, 2023, 08:55 AM by
    Full story
  • 908 Devices Launches MAVERICK for Real-Time In-Line Monitoring of Multiple Bioprocess Parameters

    Sep 25, 2023, 08:55 AM by
    MAVERICK is a Raman-based PAT solution that requires no complex modeling. It is an optical in-line analyzer that provides real-time monitoring and control of glucose, lactate, and total biomass in mammalian cell cultures, in addition to rich process fingerprint data to support large-scale efforts in predictive bioprocess modeling. MAVERICK is also the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling and development required. With its in-line optical sampling probe, biopharmaceutical scientists and engineers can quickly develop their cell culture media and design feeding and control strategies.
    Full story
  • NICE RECOMMENDS LILLY’S MIRIKIZUMAB (OMVOH ®▼) FOR THE TREATMENT OF ELIGIBLE ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

    Sep 22, 2023, 08:33 AM by
    Mirikizumab is the first IL-23p19 targeted biologic recommended by NICE for use within NHS England and Wales for treating moderately to severely active ulcerative colitis in adults.1,2. In two randomised, double-blind, placebo-controlled phase 3 trials, LUCENT-1 and LUCENT-2, mirikizumab achieved primary and key secondary endpoints, including sustained clinical remission. Decreases in bowel urgency severity were observed as early as week 2 in patients treated with mirikizumab versus placebo in LUCENT-1.2 Mirikizumab has been recommended through the NICE cost-comparison process meaning NHS England and commissioning groups have agreed to provide funding to implement this guidance within 30 days from publication of the technology appraisal guidance (TAG) rather than the standard 90 days, providing faster access to a new treatment option for eligible adults living with moderately to severely active ulcerative colitis1
    Full story
  • Alfa Chemistry: Transforming Research Possibilities through Instrumental Analytical Reagents

    Sep 22, 2023, 08:33 AM by
    Full story
  • Expanding Research Frontiers: CD Formulation Enables In Vitro Cytotoxicity Testing for Microspheres and Microneedles

    Sep 22, 2023, 08:33 AM by
    Full story
  • Bora merges with Sunway Biotech to launch global Nutraceuticals offering

    Sep 22, 2023, 08:33 AM by
    Full story
  • Health Plan of San Joaquin Selects ZeOmega to Elevate Complete Care Management

    Sep 22, 2023, 08:33 AM by
    Health Plan of San Joaquin (HPSJ) just announced they selected ZeOmega’s care management solution to support the complex health needs of 450,000+ Medi-Cal members and promote equitable care statewide. HPSJ will use ZeOmega’s platform to consolidate and analyze members’ health data to produce insights informing care needs. The partnership will empower HPSJ to support members’ physical, mental, and behavioral health needs and align with CalAIM’s whole-person approach to healthcare.
    Full story
  • Kalderos names veteran healthcare leader Angie Franks as new CEO

    Sep 21, 2023, 08:26 AM by
    Kalderos names veteran healthcare leader Angie Franks as new CEO
    Full story
  • «
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66 (current)
  • 67
  • 68
  • 69
  • 70
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy